多发性硬化治疗共识组:关于多发性硬化疾病修饰治疗的立场声明(白皮书)的解读

Interpretation of Multiple Sclerosis Therapy Consensus Group:Position Statement on Disease-modifying Therapies for Multiple Sclerosis(White Paper)

2021年德国多发性硬化(MS)治疗共识组(MSTCG)发布了最新版的“MSTCG:关于多发性硬化疾病修饰治疗的立场声明(白皮书)”,该白皮书基于最新循证医学证据,对MS的疾病修饰治疗(DMT)形成14条推荐意见,内容涵盖DMT的启动时机、治疗监测、换药策略等,旨在为临床医生提供实践指导,并为治疗决策提供科学基础。白皮书主要参考了欧洲药物获批及临床实践情况,因此在中国的适用性有一定欠缺。但整体来看该指南仍可为中国MS指南的制定提供参考依据,并一定程度上为中国的MS临床实践提供指导意见。文中将对白皮书的部分内容进行介绍和解读。

In 2021,the Multiple Sclerosis Therapy Consensus Group(MSTCG)released the latest version of"Multiple Sclerosis Therapy Consensus Group(MSTCG):position statement on diseasemodifying therapies for multiple sclerosis(white paper)".This white paper was based on the lastest evidence-based medical evidence and provides 14 recommendations on disease-modifying treatment(DMT)for MS.It covers topics including the initiation of DMT,treatment monitoring and switching strategies,aiming to provide practical guidance for clinicians and a scientific basis for treatment decisions.This white paper mainly refers to drug approvals and clinical practices in Europe,resulting in limited applicability in China.However,the guidelines can still provide a reference for the development of guidelines in China and offer guidance for clinical practice to some extent.The some contents of this white paper were introduced and interpreted.